Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma
Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma
复制标题
DOI：
10.1159/000048277
复制
发表时间：
2002-01-01
期刊：
影响因子：
3.5
通讯作者：
Tomita, K
中科院分区：
文献类型：
--
作者：
Fujiyama, S;Tanaka, M;Tomita, K
肝细胞癌（HCC）诊断的主要方法包括血清学肿瘤标志物，如甲胎蛋白、其L3级分和PIVKA-II，以及成像方式。它们并不相互关联，而是相辅相成的。因此，需要根据它们的特点设计它们的组合。首先，有必要识别出HCC的高危患者，如慢性肝炎或肝硬化患者，并在随访中定期进行血清肿瘤标志物检查。任何标记物检测呈阳性的人发展为HCC的风险最高，即使成像无法显示任何占位性病变。对高危患者进行血清学肿瘤标志物随访，结合影像学检查，可以准确评估HCC治疗的疗效。由于血清学肿瘤标志物可以比任何其他实验室检查更早地发出HCC发展的信号，因此它们提供了识别复发性HCC的极好方法。在HCC患者的管理中同样重要的是恶性肿瘤的生物学指标，治疗干预措施的选择和结果的预测。版权所有（C）2002 S. Karger AG，巴塞尔。
The mainstay for the diagnosis for hepatocellular carcinoma (HCC) includes serological tumor markers, such as alpha-fetoprotein, the L3 fraction thereof and PIVKA-II, in addition to imaging modalities. They do not correlate, but complement each other. Hence, a combination of them designed on the basis of their characteristics needs to be worked out. First, it is necessary to identify the patients at high risk for developing HCC, such as those with chronic hepatitis or liver cirrhosis, and in the follow-up conduct regular check-ups for serological tumor markers. Those testing positive for any marker are at the highest risk for developing HCC, even when imaging fails to disclose any space-occupying lesions. Following high-risk patients for serological tumor markers, in concert with imaging, makes accurate evaluation of the efficacy of therapies for HCC possible. Since serological tumor markers can signal the development of HCC earlier than any other laboratory tests, they offer excellent means of identifying relapsing HCC. Equally important in the management of patients with HCC are biological indicators for malignancy, the selection of therapeutic interventions and the prediction of the outcome. Copyright (C) 2002 S. Karger AG, Basel.